Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee injection polymer put to the test in first human trial

NCT ID NCT07611708

First seen May 29, 2026 · Last updated Jun 17, 2026 · Updated 7 times

Summary

This early study tests the safety of a single injection of a new polymer called ABR1 for knee osteoarthritis. About 25 adults with moderate to severe knee pain will receive the injection and be followed for 12 weeks. The main goal is to see if the treatment causes any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal North Shore Hospital

    Sydney, New South Wales, 2065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.